Breast Cancer
News
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
Conference Coverage
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival
BARCELONA – MONARCH 2 trial data show that adding the CDK4/6 inhibitor abemaciclib to fulvestrant significantly improves overall survival in HR+,...
News
Gene recurrence score helps predict successful combination therapy for early breast cancer
Women with a high recurrence score on a 21-gene breast cancer assay fared better with chemoendocrine therapy than expected with endocrine therapy...
News
Physicians not yet comfortable with using social media to recruit for trials
In interviews, many physicians expressed interest but would like to have institutional support, guidelines, and training.
News
AF risk is elevated after early-stage breast cancer diagnosis
The rate of AF was elevated in the first year post diagnosis and after 5 years post diagnosis, with greater elevation for women who received...
News
Mortality after breast cancer diagnosis found higher for men
Male patients had 19% higher 5-year mortality than their female counterparts even after confounders were taken into account.
News
Meta-analysis supports hormone therapy-targeted therapy combo for advanced breast cancer
A meta-analysis of 140 trials indicated that combining hormone therapy with targeted therapy led to significantly better efficacy, reducing the...
News
Ovarian function suppression gains support for premenopausal breast cancer
News
FDA issues warning for CDK 4/6 inhibitors
In a review of trials and postmarket safety databases, the FDA found there were reports of serious cases of pneumonitis, including fatalities,...